| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0378-1119(92)90727-7 |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:0378111992907277?httpAccept=text/plain |
| https://api.elsevier.com/content/article/PII:0378111992907277?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 1639266 |
| P2093 | author name string | E. Ohtsuka | |
| H. Kamiya | |||
| M. Koizumi | |||
| P2860 | cites work | Sequence requirements of the hammerhead RNA self-cleavage reaction | Q54705942 |
| Ribozymes as potential anti-HIV-1 therapeutic agents. | Q54719925 | ||
| Transformation of NIH3T3 cells with synthetic c-Ha-ras genes. | Q55260620 | ||
| A small catalytic oligoribonucleotide | Q59060304 | ||
| Non-enzymatic cleavage and ligation of RNAs complementary to a plant virus satellite RNA | Q59066021 | ||
| Construction of a series of several self-cleaving RNA duplexes using synthetic 21-mers | Q69018386 | ||
| Cleavage of specific sites of RNA by designed ribozymes | Q69044806 | ||
| Facile interconversion of duplex structures formed by copolymers of d(CG) | Q69424431 | ||
| Self-cleavage of plus and minus RNA transcripts of avocado sunblotch viroid | Q24631528 | ||
| Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase | Q26778389 | ||
| A new technique for the assay of infectivity of human adenovirus 5 DNA | Q27860797 | ||
| Self-cleaving transcripts of satellite DNA from the newt | Q28303819 | ||
| Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites | Q28304694 | ||
| Specific regulation of gene expression by antisense, sense and antigene nucleic acids | Q33256068 | ||
| Specific gene suppression by engineered ribozymes in monkey cells | Q34321871 | ||
| Mechanism of activation of a human oncogene | Q34708285 | ||
| Cellular mutation mediates T-antigen-positive revertant cells resistant to simian virus 40 transformation but not to retransformation by polyomavirus and adenovirus type 2. | Q40132562 | ||
| Mutagenesis analysis of a self-cleaving RNA. | Q40451879 | ||
| Design of RNA enzymes distinguishing a single base mutation in RNA. | Q40453502 | ||
| Ribozyme mediated destruction of RNA in vivo | Q40822323 | ||
| Simple RNA enzymes with new and highly specific endoribonuclease activities | Q43501578 | ||
| High Efficiency DNA-Mediated Transformation of Primate Cells | Q44901923 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | genetics | Q7162 |
| ribozyme | Q205858 | ||
| P304 | page(s) | 179-184 | |
| P577 | publication date | 1992-08-01 | |
| 1992-08-15 | |||
| P1433 | published in | Gene | Q5531065 |
| P1476 | title | Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene | |
| P478 | volume | 117 |
| Q72114934 | A hammerhead ribozyme inhibits ADE1 gene expression in yeast |
| Q41141669 | A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines |
| Q40524547 | Advances in cancer gene therapy |
| Q36685877 | An anti-lymphocytic choriomeningitis virus ribozyme expressed in tissue culture cells diminishes viral RNA levels and leads to a reduction in infectious virus yield |
| Q41526877 | Anti-oncogene Ribozymes for Cancer Gene Therapy |
| Q38297215 | Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects |
| Q40762899 | Antisense catalytic RNAs as therapeutic agents. |
| Q40944245 | Antisense oncogene and tumor suppressor gene therapy of cancer |
| Q40908388 | Antisense technology for cancer therapy: does it make sense? |
| Q52538349 | Attenuation of white gene expression in transgenic Drosophila melanogaster: Possible role of a catalytic antisense RNA |
| Q41449801 | Construction and characterization of lck- and fyn-specific tRNA: ribozyme chimeras |
| Q41362256 | Effect of ionizing radiation on the expression of chloramphenicol acetyltransferase gene under the control of commonly used constitutive or inducible promoters |
| Q41057162 | Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line |
| Q84152559 | Formation of supramolecular structures by negatively charged liposomes in the presence of nucleic acids and divalent cations |
| Q38313107 | Further studies on the use of oligonucleotide facilitators to increase ribozyme turnover. |
| Q40310427 | Gene targeting approach to selectively kill colon cancer cells, with hyperactive K-Ras pathway |
| Q41262158 | Gene therapeutic approaches to primary and metastatic brain tumors: II. ribozyme-mediated suppression of CD44 expression |
| Q40866190 | Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells |
| Q46686652 | H-ras ribozyme-mediated alteration of the human melanoma phenotype |
| Q34837666 | Hammerhead ribozymes for target validation |
| Q40451946 | Inhibition of gene expression with ribozymes. |
| Q43154712 | Interventional genetics and cancer treatment |
| Q41502352 | Multiple domains in a ribozyme construct confer increased suppressive activity in monkey cells. |
| Q38349720 | Oligonucleotides as modulators of cancer gene expression |
| Q38346430 | Potential clinical application of antioncogene ribozymes for human lung cancer |
| Q45856178 | Recombinant adenovirus encoding H-ras ribozyme induces apoptosis in laryngeal cancer cells through caspase- and mitochondria-dependent pathways |
| Q35897342 | Ribozyme-mediated reversal of the multidrug-resistant phenotype |
| Q33751872 | Ribozymes and the anti-gene therapy: how a catalytic RNA can be used to inhibit gene function. |
| Q41528487 | Ribozymes. Their functions and strategies for their use. |
| Q35107854 | Ribozymes: recent advances in the development of RNA tools |
| Q73363061 | Specific hammerhead ribozyme-mediated cleavage of mutant N-ras mRNA in vitro and ex vivo. Oligoribonucleotides as therapeutic agents |
| Q42833288 | Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme |
| Q40765406 | Suppression of ras oncogene-mediated transformation. |
| Q41235014 | Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes |
| Q41099705 | Targeting signal transduction for disease therapy |
| Q41611829 | Targeting signal transduction for disease therapy |
| Q40384879 | The hammerhead RNA domain, a model ribozyme |
| Q33996949 | Therapeutic genes for cancer gene therapy |
| Q73997997 | Translational suppression by hammerhead ribozymes and inactive variants in S. cerevisiae |
| Q58119623 | [49] Ribozymes in treatment of inherited retinal disease |
Search more.